False
Stu Needleman, Chief Commercial Officer at Piramal Pharma Solutions, discusses the Biosecure Act and other big trends shaking up the industry, including GLP-1s, consolidation in the CDMO sector, and sterile fill-finish. He tells us more about Piramal’s $80-million expansion in Kentucky and how the company is adapting to the changes in the market. Check out the video!
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
April 11, 2025
3 min read
In the ever volatile, highly regulated precision medicine development sector, the agility and expertise of a CDMO can make or break a commercial drug candidate.
March 6, 2025
3 min read
And getting the right people involved from the start. Here’s why collaboration is key for successful clinical development.
March 10, 2025
3 min read
From geopolitical conflicts to cyber threats, CDMOs must rethink resilience.
March 26, 2025
3 min read
With competition for skilled employees in cell and gene therapy manufacturing high, companies need to ensure they are investing in training and mentorship.
False